Amid rising investor concerns over managerial practices at Sun Pharma, the company has asked Indian securities regulators to investigate the media for reporting on whistleblower allegations that have raised questions about corporate governance.
In a letter sent last Thursday to the Securities and Exchange Board of India, the drug maker, one of India’s largest pharmaceutical companies, complained that certain individuals or firms adopted “unfair trade practices” and that “it is evident from the fact that shareholders value has been drastically eroded within a short span of time due to unsubstantiated complaints or allegations against the company and mala fide campaign launched by certain media.”
About the Author Reprints
